Newark, New Jersey 07112

  • Migraine in Adolescence

Purpose:

This is a randomized double blind trial comparing an intranasal sphenopalatine block with 2% lidocaine to intravenous (0.15 mg/kg, max 10mg) prochlorperazine in patients greater than 10 years of age presenting to a pediatric emergency department with an acute frontal migraine headache.


Study summary:

This is a randomized double blind trial comparing an intranasal sphenopalatine block with 2% lidocaine to intravenous (0.15 mg/kg, max 10mg) prochlorperazine in patients greater than 10 years of age presenting to a pediatric emergency department with an acute frontal migraine headache. Excluded populations include those with sickle cell, concern for CNS infection


Criteria:

Inclusion Criteria: - Frontal migraine headache Exclusion Criteria: - Non-english speaking - Known pregnancy - Sickle cell hemaglobinopathy - Concern for CNS infection - Acute febrile illness - non-frontal headaches - Concern for increased intracranial pressure


NCT ID:

NCT03984045


Primary Contact:

Principal Investigator
Adam Sivitz, MD
Newark Beth Israel Medical Center

Adam Sivitz, MD
Phone: 973 926 2484
Email: adam.sivitz@rwjbh.org


Backup Contact:

N/A


Location Contact:

Newark, New Jersey 07112
United States

Adam Sivitz, MD
Phone: 973-926-2484
Email: adam.sivitz@rwjbh.org

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: October 02, 2022

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.